biodefense News
Most Popular biodefense Story
Avant, Celldex merge in $115M stock deal
Avant Immunotherapeutics is merging with Celldex Therapeutics in a stock deal valued at $115 million. Celldex shareholders will wind up with a majority of the shares in the merged company, which will... Read more...
Latest Headlines
- October 22, 2007
- January 21, 2007
- January 8, 2007
- January 8, 2007
- December 20, 2006
- October 4, 2006
- September 27, 2006
- September 27, 2006
- August 14, 2006
- July 20, 2006
- June 19, 2006
- June 8, 2006
- April 9, 2006
- March 13, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
